How I treat acute myeloid leukemia in the era of new drugs
CD DiNardo, AH Wei - Blood, The Journal of the American …, 2020 - ashpublications.org
The acute myeloid leukemia (AML) treatment landscape has changed substantially since
2017. New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2 …
2017. New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2 …
Acute myeloid leukemia: 2019 update on risk‐stratification and management
EH Estey - American journal of hematology, 2018 - Wiley Online Library
Outcome in patients with acute myeloid leukemia (AML) ranges from death within a few days
of beginning treatment (treatment related mortality, TRM) to likely cure. The major reason …
of beginning treatment (treatment related mortality, TRM) to likely cure. The major reason …
Gemtuzumab ozogamicin for acute myeloid leukemia
FR Appelbaum, ID Bernstein - Blood, The Journal of the …, 2017 - ashpublications.org
Abstract On 1 September 2017, the US Food and Drug Administration (FDA) approved
gemtuzumab ozogamicin (GO) for the treatment of adults with newly diagnosed CD33+ …
gemtuzumab ozogamicin (GO) for the treatment of adults with newly diagnosed CD33+ …
Biological and clinical consequences of NPM1 mutations in AML
Acute myeloid leukemia (AML) is characterized by accumulation of myeloid cells in the bone
marrow because of impaired differentiation and proliferation, resulting in hematopoietic …
marrow because of impaired differentiation and proliferation, resulting in hematopoietic …
[HTML][HTML] Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
L Tang, Z Huang, H Mei, Y Hu - Signal Transduction and Targeted …, 2023 - nature.com
The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …
understanding of both the mechanisms of immune responsiveness and immune escape …
CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III Children's …
Purpose Gemtuzumab ozogamicin (GO), a CD33-targeted immunoconjugate, is a re-
emerging therapy for acute myeloid leukemia (AML). CD33 single nucleotide polymorphism …
emerging therapy for acute myeloid leukemia (AML). CD33 single nucleotide polymorphism …
Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia
J Baron, ES Wang - Expert review of clinical pharmacology, 2018 - Taylor & Francis
Introduction: Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a
monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin …
monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin …
The clinical development of antibody–drug conjugates—lessons from leukaemia
E Jabbour, S Paul, H Kantarjian - Nature Reviews Clinical Oncology, 2021 - nature.com
Advances in our understanding of cancer biology have enabled drug development to
progress towards better targeted therapies that are both more effective and safer owing to …
progress towards better targeted therapies that are both more effective and safer owing to …
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia
E Fournier, N Duployez, B Ducourneau… - Blood, The Journal …, 2020 - ashpublications.org
Acute myeloid leukemia (AML) is a highly heterogeneous disease both in terms of genetic
background and response to chemotherapy. Although molecular aberrations are routinely …
background and response to chemotherapy. Although molecular aberrations are routinely …